Elaris

ELARIS is developing next-generation vaccines to prevent serious bacterial infections, focusing on diseases with significant unmet medical need. Vaccines have transformed public health, and ELARIS was founded to extend that impact to bacterial diseases that disproportionately burden aging and vulnerable populations.

As immune function declines with age, bacterial infections become more frequent and severe—often leading to hospitalization, recurrent illness, antibiotic exposure, and loss of independence. We believe healthy aging begins with prevention, so we are focused on stopping serious infections before they take hold.

Our lead program is a highly differentiated vaccine against Clostridioides difficile, a severe hospital-acquired diarrheal infection that particularly affects elderly patients. Guided by rigorous science and a commitment to real-world impact, ELARIS is advancing bacterial vaccines designed to preserve health and quality of life.